Suppr超能文献

采用斑点印迹法、酶联免疫吸附测定法和蛋白质印迹法对接受伊曲康唑治疗的副球孢子菌病患者进行血清学随访。

Serological follow-up of patients with paracoccidioidomycosis treated with itraconazole using Dot-blot, ELISA and western-blot.

作者信息

Martins R, Marques S, Alves M, Fecchio D, de Franco M F

机构信息

Department of Pathology, Faculty of Medicine, State University Júlio Mesquita Filho, UNESP, São Paulo, Brazil.

出版信息

Rev Inst Med Trop Sao Paulo. 1997 Sep-Oct;39(5):261-9. doi: 10.1590/s0036-46651997000500004.

Abstract

Twenty-seven mycologically proven cases of paracoccidioidomycosis (PCM) were treated with itraconazole (100-200 mg/day in month 1 and 100 mg/day until month 6-8) and evaluated clinically and serologically, up to 3.5 years post-therapy, using Dot-blot and ELISA for measuring the titers of IgG, IgA and IgM anti-P.brasiliensis antibodies and Western-blot for determining IgG, IgA and IgM antibodies against the antigen components of the fungus. Before treatment, 81.5% (Dot-blot) and 84% (ELISA) of the patients presented elevated IgG anti-P.brasiliensis antibody titers which dropped slightly with treatment. On the other hand, the percentages of pre-treatment high-titered sera for IgA and IgM anti-P.brasiliensis were lower (51.9% and 51.8%: Dot-blot; 16.5 and 36%: ELISA, respectively) but the titers tended to become negative more frequently with treatment. Prior to treatment, the percentages of positivity for IgG, IgA and IgM anti-P.brasiliensis antibodies in Western-blot were 96%, 20.8% and 41.6%, respectively. Antigens with molecular weights varying from 16-78 kDa, from 21-76 kDa and from 27-78 kDa were reactive for IgG, IgA and IgM antibodies, respectively. The most frequently reactive antigenic components had molecular weights of 27, 33 and 43 kDa for IgG, and 70 for IgA and IgM antibodies. During the period of study, the patients responded well to treatment. The present data confirm the diversity and complexity of the humoral response in PCM, and the importance of utilizing different serological tests to detect IgG, IgA and IgM anti-P. brasiliensis antibodies.

摘要

对27例经真菌学证实的副球孢子菌病(PCM)患者采用伊曲康唑进行治疗(第1个月100 - 200mg/天,直至第6 - 8个月为100mg/天),并在治疗后长达3.5年的时间里进行临床和血清学评估,使用斑点印迹法和酶联免疫吸附测定法(ELISA)检测抗巴西副球孢子菌IgG、IgA和IgM抗体的滴度,以及使用蛋白质印迹法测定针对该真菌抗原成分的IgG、IgA和IgM抗体。治疗前,81.5%(斑点印迹法)和84%(ELISA法)的患者抗巴西副球孢子菌IgG抗体滴度升高,治疗后略有下降。另一方面,治疗前抗巴西副球孢子菌IgA和IgM高滴度血清的百分比更低(分别为51.9%和51.8%:斑点印迹法;16.5%和36%:ELISA法),但随着治疗,滴度更频繁地趋于转阴。治疗前,蛋白质印迹法中抗巴西副球孢子菌IgG、IgA和IgM抗体的阳性百分比分别为96%、20.8%和41.6%。分子量在16 - 78kDa、21 - 76kDa和27 - 78kDa之间的抗原分别与IgG、IgA和IgM抗体发生反应。最常发生反应的抗原成分,IgG对应的分子量为27、33和43kDa,IgA和IgM抗体对应的分子量为70kDa。在研究期间,患者对治疗反应良好。目前的数据证实了PCM中体液反应的多样性和复杂性,以及利用不同血清学检测方法检测抗巴西副球孢子菌IgG、IgA和IgM抗体的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验